Pfizer's fourth-quarter earnings fell 59% as the drug maker continued to face challenges from major drugs that have lost market exclusivity.
from WSJ.com: US Business http://ift.tt/1d69Kf9
via IFTTT
from WSJ.com: US Business http://ift.tt/1d69Kf9
via IFTTT
No comments:
Post a Comment